Jennifer A Muszynski1, Rajan Thakkar, Mark W Hall. 1. aCritical Care Medicine bThe Research Institute cDepartment of Pediatric Surgery, Nationwide Children's Hospital, Columbus, Ohio, USA.
Abstract
PURPOSE OF REVIEW: The purpose of review is to highlight the inflammatory response in critical illness and the importance of immune monitoring and modulation in the diagnosis and treatment of critical illness-induced innate immune suppression. RECENT FINDINGS: The pro and anti-inflammatory responses are known to be concurrently activated in many patients requiring intensive care, with innate immune suppression emerging as an important, and potentially reversible, complication of critical illness. SUMMARY: The initial inflammatory response to critical illness is typically driven by innate immune cells, including neutrophils, monocytes, and macrophages. The proinflammatory mediators made by these cells are responsible for many of the pathophysiologic features of critical illness. Concurrent with this, however, is a compensatory anti-inflammatory response, including the elaboration of anti-inflammatory mediators and impairment of innate immune cell function. This includes reduction of monocyte human leukocyte antigen-DR expression and impairment of the ability of innate immune cells to produce tumor necrosis factor alpha when stimulated ex vivo. In its most severe form this is referred to as immunoparalysis, and is associated with markedly increased risks for secondary infection and death in the ICU. Prospective testing can detect this phenomenon, and immunostimulatory strategies, including the use of granulocyte macrophage-colony stimulating factor, have the potential to restore innate immune function in this setting.
PURPOSE OF REVIEW: The purpose of review is to highlight the inflammatory response in critical illness and the importance of immune monitoring and modulation in the diagnosis and treatment of critical illness-induced innate immune suppression. RECENT FINDINGS: The pro and anti-inflammatory responses are known to be concurrently activated in many patients requiring intensive care, with innate immune suppression emerging as an important, and potentially reversible, complication of critical illness. SUMMARY: The initial inflammatory response to critical illness is typically driven by innate immune cells, including neutrophils, monocytes, and macrophages. The proinflammatory mediators made by these cells are responsible for many of the pathophysiologic features of critical illness. Concurrent with this, however, is a compensatory anti-inflammatory response, including the elaboration of anti-inflammatory mediators and impairment of innate immune cell function. This includes reduction of monocyte human leukocyte antigen-DR expression and impairment of the ability of innate immune cells to produce tumor necrosis factor alpha when stimulated ex vivo. In its most severe form this is referred to as immunoparalysis, and is associated with markedly increased risks for secondary infection and death in the ICU. Prospective testing can detect this phenomenon, and immunostimulatory strategies, including the use of granulocyte macrophage-colony stimulating factor, have the potential to restore innate immune function in this setting.
Authors: Philip J Norris; Ken Schechtman; Heather C Inglis; Avril Adelman; John W Heitman; Ryan Vilardi; Avani Shah; Nareg H Roubinian; Ali Danesh; Anne M Guiltinan; Sheila M Keating; Jacques Lacroix; Mitchell J Cohen; Philip C Spinella Journal: Transfusion Date: 2019-03-18 Impact factor: 3.157
Authors: Joseph A Carcillo; Bradley Podd; Rajesh Aneja; Scott L Weiss; Mark W Hall; Timothy T Cornell; Thomas P Shanley; Lesley A Doughty; Trung C Nguyen Journal: Pediatr Crit Care Med Date: 2017-03 Impact factor: 3.624
Authors: Jaroslav G Vostal; Paul W Buehler; Monique P Gelderman; Abdu I Alayash; Alan Doctor; James C Zimring; Simone A Glynn; John R Hess; Harvey Klein; Jason P Acker; Philip C Spinella; Angelo D'Alessandro; Bernhard Palsson; Thomas J Raife; Michael P Busch; Timothy J McMahon; Marcos Intaglietta; Harold M Swartz; Michael A Dubick; Sylvain Cardin; Rakesh P Patel; Charles Natanson; John W Weisel; Jennifer A Muszynski; Philip J Norris; Paul M Ness Journal: Transfusion Date: 2017-12-15 Impact factor: 3.157
Authors: Catherine Madurski; Jessica M Jarvis; Sue R Beers; Amy J Houtrow; Amy K Wagner; Anthony Fabio; Chunyan Wang; Craig M Smith; Lesley Doughty; Keri Janesko-Feldman; Pamela Rubin; Dorothy Pollon; Amery Treble-Barna; Patrick M Kochanek; Ericka L Fink Journal: Neurocrit Care Date: 2021-03-04 Impact factor: 3.532
Authors: Patrick M Siegel; Lukas Orlean; István Bojti; Klaus Kaier; Thilo Witsch; Jennifer S Esser; Georg Trummer; Martin Moser; Karlheinz Peter; Christoph Bode; Philipp Diehl Journal: Front Cardiovasc Med Date: 2021-07-19
Authors: Rajan K Thakkar; Racheal Devine; Jill Popelka; Josey Hensley; Renata Fabia; Jennifer A Muszynski; Mark W Hall Journal: J Burn Care Res Date: 2021-05-07 Impact factor: 1.845
Authors: Avraham Unterman; Tomokazu S Sumida; Nima Nouri; Xiting Yan; Amy Y Zhao; Victor Gasque; Jonas C Schupp; Hiromitsu Asashima; Yunqing Liu; Carlos Cosme; Wenxuan Deng; Ming Chen; Micha Sam Brickman Raredon; Kenneth B Hoehn; Guilin Wang; Zuoheng Wang; Giuseppe DeIuliis; Neal G Ravindra; Ningshan Li; Christopher Castaldi; Patrick Wong; John Fournier; Santos Bermejo; Lokesh Sharma; Arnau Casanovas-Massana; Chantal B F Vogels; Anne L Wyllie; Nathan D Grubaugh; Anthony Melillo; Hailong Meng; Yan Stein; Maksym Minasyan; Subhasis Mohanty; William E Ruff; Inessa Cohen; Khadir Raddassi; Laura E Niklason; Albert I Ko; Ruth R Montgomery; Shelli F Farhadian; Akiko Iwasaki; Albert C Shaw; David van Dijk; Hongyu Zhao; Steven H Kleinstein; David A Hafler; Naftali Kaminski; Charles S Dela Cruz Journal: Nat Commun Date: 2022-01-21 Impact factor: 17.694